Neothetics is a clinical-stage specialty pharmaceutical company focusing on the development of therapeutics for the aesthetic market. Its flagship product, LIPO-202, presents the potential to become a leading injection for localized fat reduction and body contouring. The company's offering of a non-surgical procedure with a minimal time commitment of approximately five minutes, providing an effective and safe solution for reducing abdominal bulging in non-obese patients, without any downtime, sets it apart in the market.
Established in the United States, Neothetics operates within the Health Care, Health and Wellness, and Pharmaceutical industries.
Notably, the company received a significant $8.00M Series C investment on 11 February 2014. The investment was sourced from Alta Partners, Domain Associates, and AKS Capital.